keyword
MENU ▼
Read by QxMD icon Read
search

Orbera gastric balloon

keyword
https://www.readbyqxmd.com/read/29579540/pancreatitis-from-intra-gastric-balloon-insertion-case-report-and-literature-review
#1
Neel Gore, Praveen Ravindran, Daniel Leonard Chan, Kamalakanta Das, Peter H Cosman
INTRODUCTION: Intra-Gastric Balloon (IGB) is increasingly used as a non-operative management strategy in bariatric patients. However, as IGB use has become more prevalent, new potentially life-threatening adverse effects have emerged. We report a case of IGB-related acute pancreatitis from a tertiary referral hospital. A literature review of electronic databases was conducted to identify other cases PRESENTATION OF CASE: A 20-year-old female presented to the emergency department with acute onset of epigastric pain on day-1 post-insertion of an IGB (Orbera® )...
March 16, 2018: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/29425781/single-fluid-filled-intragastric-balloon-safe-and-effective-for-inducing-weight-loss-in-a-real-world-population
#2
Eric J Vargas, Carl M Pesta, Ahmad Bali, Eric Ibegbu, Fateh Bazerbachi, Rachel L Moore, Vivek Kumbhari, Reem Z Sharaiha, Trace W Curry, Gina DosSantos, Ramsey Schmitz, Abhishek Agnihotri, Aleksey A Novikov, Tracy Pitt, Margo K Dunlap, Andrea Herr, Louis Aronne, Erin Ledonne, Hoda C Kadouh, Lawrence J Cheskin, Manpreet S Mundi, Andres Acosta, Christopher J Gostout, Barham K Abu Dayyeh
BACKGROUND & AIMS: The Orbera intragastric balloon (OIB) is a single fluid-filled intragastric balloon approved for induction of weight loss and treatment of obesity. However, little is known about the effectiveness and safety of outside clinical trials, and since approval, the Food and Drug Administration has issued warnings to health care providers about risk of balloon hyperinflation requiring early removal, pancreatitis, and death. We analyzed data on patients who have received the OIB since its approval to determine its safety, effectiveness, and tolerance in real-world clinical settings...
February 7, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29071537/major-gastric-haemorrhage-after-intragastric-balloon-insertion-case-report
#3
Romy J Granek, Michael W Hii, Salena M Ward
Intragastric balloons are a minimally invasive option for weight loss. They are generally well tolerated and rarely associated with serious adverse events. We report a case of major upper gastrointestinal haemorrhage after insertion of an Orbera® intragastric balloon.
January 2018: Obesity Surgery
https://www.readbyqxmd.com/read/28707286/intragastric-balloon-treatment-for-obesity-review-of-recent-studies
#4
REVIEW
Chinara M Tate, Allan Geliebter
INTRODUCTION: The FDA recently approved three intragastric balloon (IGB) devices, ReShape, ORBERA™, and Obalon for treatment of obesity. Given the high cost, complication risk, and invasiveness of bariatric surgery, IGB treatment may present a safer and lower cost option for weight reduction. IGBs are generally placed in the stomach endoscopically for up to 6 months to reduce gastric capacity, enhance feelings of fullness, and induce weight loss. The mechanism of action likely involves stimulation of gastric mechanoreceptors triggering short-acting vagal signals to brain regions implicated in satiety...
August 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28421456/filling-the-void-a-review-of-intragastric-balloons-for-obesity
#5
REVIEW
Patrick Laing, Tuan Pham, Linda Jo Taylor, John Fang
Endoscopic bariatric therapies are predicted to become much more widely used in North America for obese patients who are not candidates for bariatric surgery. Of all the endoscopic bariatric therapies, intragastric balloons (IGBs) have the greatest amount of clinical experience and published data supporting their use. Three IGBs are FDA approved and are now commercially available in the USA (Orbera, ReShape Duo, and Obalon) with others likely soon to follow. They are generally indicated for patients whose BMI ranges from 30 to 40 mg/kg2 and who have failed to lose weight with diet and exercise...
June 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28017964/intragastric-balloon-as-an-adjunct-to-lifestyle-intervention-a-randomized-controlled-trial
#6
RANDOMIZED CONTROLLED TRIAL
A Courcoulas, B K Abu Dayyeh, L Eaton, J Robinson, G Woodman, M Fusco, V Shayani, H Billy, D Pambianco, C Gostout
BACKGROUND/OBJECTIVES: This trial evaluated the safety and effectiveness of the Orbera Intragastric Balloon as an adjunct to lifestyle intervention. SUBJECTS/METHODS: In this multicenter, randomized, open-label clinical trial, 255 adults with a body mass index of 30-40 kg m- 2 were treated and outcomes were assessed up to 12 months. Participants were randomized to endoscopic placement of an intragastric balloon plus lifestyle or lifestyle intervention alone...
March 2017: International Journal of Obesity: Journal of the International Association for the Study of Obesity
https://www.readbyqxmd.com/read/26305524/reshape-and-orbera-two-gastric-balloon-devices-for-weight-loss
#7
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
August 31, 2015: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/26240686/endoscopic-therapy-for-weight-loss-gastroplasty-duodenal-sleeves-intragastric-balloons-and-aspiration
#8
REVIEW
Nitin Kumar
A new paradigm in the treatment of obesity and metabolic disease is developing. The global obesity epidemic continues to expand despite the availability of diet and lifestyle counseling, pharmacologic therapy, and weight loss surgery. Endoscopic procedures have the potential to bridge the gap between medical therapy and surgery. Current primary endoscopic bariatric therapies can be classified as restrictive, bypass, space-occupying, or aspiration therapy. Restrictive procedures include the USGI Primary Obesity Surgery Endolumenal procedure, endoscopic sleeve gastroplasty using Apollo OverStitch, TransOral GAstroplasty, gastric volume reduction using the ACE stapler, and insertion of the TERIS restrictive device...
July 25, 2015: World Journal of Gastrointestinal Endoscopy
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"